On October 15, Gelonhui announced that Beijing SL Pharmaceutical (002038.SZ) recently received the "Drug Registration Certificate" for the approval and issuance of Etirasstan injection (trade name: Yivin) (10ml:20mg) from the National Medical Products Administration.
Etirasstan is a specific platelet glycoprotein IIb/IIIa receptor antagonist, which reverses the ischemic state caused by thrombosis by selectively and reversibly inhibiting the final common pathway of platelet aggregation. Clinically, it is mainly used for post-interventional anti-thrombotic treatment in patients with acute coronary syndrome, and can also be used for the treatment of non-atherosclerotic vascular diseases and thrombosis.
This product is listed as a Class B variety in the National Medical Insurance Catalog. In July 2022, it was included in the seventh batch of products in the national centralized bidding procurement catalog. Up to now, eight companies with the same specifications of this product have passed the consistency evaluation, and the approval of the company's product this time is considered equivalent to passing the consistency evaluation.
